Literature DB >> 21357649

Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.

S Wilgenhof1, B Neyns2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21357649     DOI： 10.1093/annonc/mdr028

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  61 in total

Review 1.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

2.  Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.

Authors:  Douglas B Johnson; Debra L Friedman; Elizabeth Berry; Ilka Decker; Fei Ye; Shilin Zhao; Alicia K Morgans; Igor Puzanov; Jeffrey A Sosman; Christine M Lovly
Journal:  Cancer Immunol Res       Date:  2015-02-03       Impact factor: 11.151

Review 3.  Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.

Authors:  Dustin Anderson; Grayson Beecher; Nabeela Nathoo; Michael Smylie; Jennifer A McCombe; John Walker; Rajive Jassal
Journal:  Neurooncol Pract       Date:  2018-10-04

4.  Guillain-Barré syndrome in patients treated with immune checkpoint inhibitors.

Authors:  Qianqian Fan; Yang Hu; Xiang Wang; Bin Zhao
Journal:  J Neurol       Date:  2021-01-21       Impact factor: 4.849

Review 5.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 6.  Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Authors:  Christophoros Astaras; Rita de Micheli; Bianca Moura; Thomas Hundsberger; Andreas F Hottinger
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-01       Impact factor: 5.081

7.  Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.

Authors:  Douglas B Johnson; Vita Saranga-Perry; Patrick J M Lavin; W Bryan Burnette; Stephen W Clark; David R Uskavitch; Deborah E Wallace; Mark A Dickson; Ragini R Kudchadkar; Jeffrey A Sosman
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 8.  Immune-related Adverse Events in Cancer Patients.

Authors:  Daniel J Pallin; Christopher W Baugh; Michael A Postow; Jeffrey M Caterino; Timothy B Erickson; Gary H Lyman
Journal:  Acad Emerg Med       Date:  2018-05-25       Impact factor: 3.451

9.  Haploinsufficiency of immune checkpoint receptor CTLA4 induces a distinct neuroinflammatory disorder.

Authors:  Matthew K Schindler; Stefania Pittaluga; Yoshimi Enose-Akahata; Helen C Su; V Koneti Rao; Amy Rump; Steven Jacobson; Irene Cortese; Daniel S Reich; Gulbu Uzel
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 10.  Toxicity management of immunotherapy for patients with metastatic melanoma.

Authors:  Helena Linardou; Helen Gogas
Journal:  Ann Transl Med       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.